Univariate analysis of factors associated with adverse outcome in 91 pediatric and adolescent patients undergoing allogeneic transplantation for recurring Hodgkin lymphoma
| Variable . | Type . | P . |
|---|---|---|
| Nonrelapse mortality | ||
| Sex | Female vs male | .03 |
| Donor relation | Mismatched vs matched | .05 |
| Status at HSCT | Refractory vs sensitive | .09 |
| Performance status | Poor vs good | .09 |
| CMV status donor/recipient | Neg/neg vs others | .10 |
| Relapse rate | ||
| Performance status | Poor vs good | .002 |
| Status at HSCT | Refractory vs sensitive | .008 |
| Type of conditioning* | Reduced intensity vs myeloablative | .01 |
| Progression-free survival | ||
| Status of HSCT | Refractory vs sensitive | .001 |
| Performance status | Poor vs good | .001 |
| Type of conditioning | Reduced intensity vs myeloablative | .02 |
| Sex | Female vs male | .04 |
| CMV status of donor/recipient | Neg/neg vs others | .05 |
| Overall survival | ||
| Status at HSCT | Refractory vs sensitive | .01 |
| Performance status | Poor vs good | .01 |
| CMV status of donor/recipient | Neg/neg vs others | .02 |
| Time to allogeneic HSCT | < 36 mos vs ≥ 36 mos | .04 |
| Sex | Female vs male | .04 |
| Variable . | Type . | P . |
|---|---|---|
| Nonrelapse mortality | ||
| Sex | Female vs male | .03 |
| Donor relation | Mismatched vs matched | .05 |
| Status at HSCT | Refractory vs sensitive | .09 |
| Performance status | Poor vs good | .09 |
| CMV status donor/recipient | Neg/neg vs others | .10 |
| Relapse rate | ||
| Performance status | Poor vs good | .002 |
| Status at HSCT | Refractory vs sensitive | .008 |
| Type of conditioning* | Reduced intensity vs myeloablative | .01 |
| Progression-free survival | ||
| Status of HSCT | Refractory vs sensitive | .001 |
| Performance status | Poor vs good | .001 |
| Type of conditioning | Reduced intensity vs myeloablative | .02 |
| Sex | Female vs male | .04 |
| CMV status of donor/recipient | Neg/neg vs others | .05 |
| Overall survival | ||
| Status at HSCT | Refractory vs sensitive | .01 |
| Performance status | Poor vs good | .01 |
| CMV status of donor/recipient | Neg/neg vs others | .02 |
| Time to allogeneic HSCT | < 36 mos vs ≥ 36 mos | .04 |
| Sex | Female vs male | .04 |
Factors with a P value <.1 are listed.
CMV indicates cytomegalovirus; HSCT, hematopoietic stem cell transplantation; neg, negative; RIC, reduced-intensity conditioning; and vs, versus.
Higher relapse and progression rate for patients after RIC starting 9 months after HSCT.